Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting – PRNewswire
Posted: May 26, 2021 at 1:59 am
CRANFORD, N.J., May 25, 2021 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it has received the Best Poster Award at the prestigious International Society for Cell and Gene Therapy (ISCT) 2021 Annual Meeting.
The poster, titled "Novel Induced-Mesenchymal Stem Cells (i-MSCs) Attenuate Severity of ARDS in Septic Sheep," will be presented today, May 25, 2021 by Dr. Perenlei Enkhbaatar, Professor and Director of the Translational Intensive Care Unit at The University of Texas Medical Branch.
"The ISCT annual meeting brings together the brightest minds in cell and gene therapy and highlights cutting edge research in the field," stated Dr. Myron Czuczman, Chief Medical Officer and Executive Vice President of Citius. "We are honored to be selected for the Best Poster Award from among this distinguished peer group. The interim results demonstrate a marked improvement in i-MSC treated animals over control animals in key clinical parameters including: improved oxygenation, less systemic shock, and reduced bacterial burden and vascular injury to the lungs. We are encouraged by the data and welcome the support and engagement of the scientific research community," concluded Dr. Czuczman.
Myron Holubiak, President and Chief Executive Officer of Citius added, "We are grateful to be recognized by our peers for this award as we advance our novel stem cell program for the treatment of ARDS. In parallel to the expansion of our proof-of-concept ARDS sheep study, we are following guidance from the U.S. Food and Drug Administration (FDA) in the development of a cGMP Master Cell Bank of i-MSCs. I am pleased to report that we have completed the development of an i-MSC Accession Cell Bank (ACB) which is to serve as the basis for a scalable cGMP compliant manufacturing capability to support all of our planned pre-clinical and clinical trials. Compared with donor-derived cells that require a continuous supply of new donors, we believe our i-MSCs,derived from a single clonal induced pluripotent stem cell (iPSC), offer multiple advantages including consistent and scalable manufacturing and a potentially limitless supply of i-MSCs to meet our future needs. Moreover, we believe that our i-MSC stem cell program has the potential to meaningfully impact the treatment of ARDS and we appreciate the recognition received from the cell and gene therapy community as we advance our program."
Citius' i-MSCs are derived from iPSCs originating from a qualified single-donor dermal fibroblast, resulting in one homogeneous, validated source for all future cells. A patented synthetic, non-immunogenic mRNA high efficiency cell reprogramming technique is applied to create a clonal iPSC Master Cell Bank from which our i-MSCs are differentiated and expanded to create an i-MSC Accession Cell Bank. Citius has completed the development of its i-MSC ACB and is currently testing (as per FDA guidance) and expanding the cells to create an allogeneic cGMP i-MSC Master Cell Bank to support all future i-MSC needs.
The poster will be available to conference attendees via the conference website. The poster will be available on Citius' website once the event commences.
Conference Details:
Abstract Title:
"Novel Induced-Mesenchymal Stem Cells (i-MSCs) Attenuate Severity of ARDS in Septic Sheep"
Authors:
K. Hashimoto, N. Bazhanov, P. Enkhbaatar, M. Angel, A. Lader, M. Czuczman, and M. Matthay
Abstract Number:
100
Date and Time:
May 25, 2021
Session I
12:30 2:00 PM EDT
Session II
8:00 9:30 PM EDT
About Acute Respiratory Distress Syndrome (ARDS)
ARDS is an inflammatory process leading to build-up of fluid in the lungs and respiratory failure. It can occur due to infection, trauma and inhalation of noxious substances. ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation. Survivors of ARDS are often left with severe long-term illness and disability. ARDS is a frequent complication of patients with COVID-19. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company's lead product candidate, Mino-Lok, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial. Mino-Lok was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. For more information, please visit http://www.citiuspharma.com.
Safe Harbor
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks relating to the results of research and development activities, including those for our NoveCite stem cell therapy; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our dependence on third-party suppliers; our ability to successfully undertake and complete clinical trials and the results from those trials for our product candidates; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our need for substantial additional funds; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to attract, integrate, and retain key personnel; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our ability to procure cGMP commercial-scale supply; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by Covid-19. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ("SEC") filings which are available on the SEC's website at http://www.sec.gov, including in our Annual Report on Form 10-K for the year ended September 30, 2020, filed with the SEC on December 16, 2020 and updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Investor Relations for Citius Pharmaceuticals:
Andrew ScottVice President, Special ProjectsT: 908-967-6677 x105E: [emailprotected]
Ilanit AllenVice President, Corporate Communications and Investor RelationsT: 908-967-6677 x113E: [emailprotected]
SOURCE Citius Pharmaceuticals, Inc.
Continue reading here:
Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting - PRNewswire
- A dive into the genetic history of India, and the role of vitamin A in skin repair - Science - March 12th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 12th, 2024
- Fiona M. Watt receives the 2024 ISSCR Achievement Award for her seminal work with skin stem cells - EurekAlert - February 13th, 2024
- Eggs from men, sperm from women: Stem cell therapy may just turn reproduction upside down! - The Economic Times - January 20th, 2024
- Herbosa: Clinic under probe after skin treatments linked to womans death - Philstar.com - January 20th, 2024
- These Will Be the Biggest Skin-Care Trends of 2024 - Allure - December 25th, 2023
- Defence Mechanisms: Four ways your body is protecting you every time you fall sick - indulgexpress - May 13th, 2023
- Treat Yourself to a Spa Day With a $100 Deal on $600 Worth of Products From Elemis, 111SKIN, Nest & More - E! NEWS - May 13th, 2023
- Cell-Based Regenerative Medicine Market Size to Witness Rapid Growth at a CAGR of 15% by 2032 | insightSLICE - EIN News - May 5th, 2023
- Best EGF Serum (Epidermal Growth Factor Serum) In 2023: Discover the Ultimate In Skin Rejuvenation - Outlook India - April 18th, 2023
- 7-year-old vows to find a cure for brother in need of bone marrow transplant - WJLA - February 26th, 2023
- 10th Annual Regenerative Medicine Essentials Course and World Stem Cell Summit Return to Live with Virtual Option in 2023 - Newswise - February 10th, 2023
- Leukaemia signs and symptoms: How to detect, treat the aggressive blood cancer - Hindustan Times - February 10th, 2023
- Adult stem cell - Wikipedia - December 28th, 2022
- Stem cells: a brief history and outlook - Science in the News - December 28th, 2022
- What are totipotent stem cells & what can they do? - The Niche - December 28th, 2022
- Certain Foods Discovered to Increase Stem Cells, Cell Regeneration - December 28th, 2022
- Skin Cell - The Definitive Guide | Biology Dictionary - December 28th, 2022
- Women are using menstrual blood for skincare here's why I think beauty has gone too far this time - VOGUE India - December 4th, 2022
- Mesenchymal Stem Cells | Properties, Process, Functions, & Therapies - November 26th, 2022
- Childbirth - Wikipedia - November 26th, 2022
- Unlocking the Mysteries of Brain Regeneration Groundbreaking Study Offers New Insight - SciTechDaily - September 30th, 2022
- TikTok Made Me Buy It: The Creamy Concealer That Instantly Veils Dark Circles and Hyperpigmentation - Vogue - September 30th, 2022
- Here Is Why You Heal Slower As You Age - Health Digest - September 30th, 2022
- A glimpse into Indian consumers expectations for cosmetic treatments and consumption insights - The Financial Express - September 30th, 2022
- Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027 -... - September 30th, 2022
- Hair-bearing human skin generated entirely from pluripotent stem cells - September 13th, 2022
- FACTORFIVE Skincare The Power of Stem Cells for Skin - September 13th, 2022
- Stem cells: Sources, types, and uses - Medical News Today - September 13th, 2022
- Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions - September 13th, 2022
- Top 3 grants in regenerative medicine: July 2022 - RegMedNet - September 13th, 2022
- Beauty maybe be skin deep, but AI finds revenue on the faces surface - Biometric Update - September 13th, 2022
- September is Blood Cancer Awareness Month: All You Need to Know - News18 - September 13th, 2022
- 10 Facts That Prove Memory Is Not What You Think - Listverse - September 13th, 2022
- Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) and PADCEV... - September 13th, 2022
- NYC Dermatologist, Dr. Julie Russak, launches first Anti-Aging Wellness Program of its kind in the U.S. - PR Web - September 13th, 2022
- Curbing COVID-Related Hair Loss: Russak Dermatology's Hair Restoration Therapy - PR Web - August 11th, 2022
- Jennifer Aniston And Sandra Oh Swear By This Moisturizer That Shoppers Say Created Permanent Changes To Their Skin - Suggest - August 11th, 2022
- Victoria Beckham and Kim Kardashian are fans of Augustinus Baders skincare range - and you can get 20% off - The Mirror - August 11th, 2022
- How your intestines repair and renew themselves - Futurity: Research News - August 3rd, 2022
- Bone marrow imaging reveals the migration dynamics of neonatal hematopoietic stem cells | Communications Biology - Nature.com - August 3rd, 2022
- Global Stem Cells Group Expands Its Stem Cell Therapy and Regenerative Medicine Centers to Indonesia - GlobeNewswire - August 3rd, 2022
- NuFace Is Having a Major Sale During Amazon Prime Day 2022 See Deals on Trinity, NuBody, and More - Allure - July 17th, 2022
- Global Stem Cell Manufacturing Market Value Projected To Reach USD 21.71 Billion By 2029, Registering A CAGR Of 9.1% - Digital Journal - July 17th, 2022
- The 'Benjamin Button' effect: Scientists can reverse aging in mice. The goal is to do the same for humans - KITV Honolulu - July 17th, 2022
- Why do some women struggle to breastfeed? A UCSC researcher on what we know, and don't - Lookout Santa Cruz - July 17th, 2022
- What if we could genetically dial back our skin? - The Week - June 28th, 2022
- Reviewers Are Calling This Hydrating Stem Cell Cream Miraculous - Us Weekly - June 28th, 2022
- UVR Promotes Keratinocyte Phagocytosis and Skin Pigmentation Through T | CCID - Dove Medical Press - June 28th, 2022
- 'A new Alzheimer's treatment is on the horizon': Cell therapy reverses dementia-like syndrome in dogs - BioPharma-Reporter.com - June 28th, 2022
- What Is Vegan Collagen? And the 6 Best Products to Try - VegNews - June 28th, 2022
- Shock Wave Uses and Benefits The Horse - TheHorse.com - June 28th, 2022
- Chao Discusses Stratifying and Treating Patients With Graft-Vs-Host Disease - Targeted Oncology - June 28th, 2022
- Elucidating the developmental origin of life-sustaining adrenal glands | Penn Today - Penn Today - May 24th, 2022
- All Things Hot In The Beauty Space In The Month Of May | Femina.in - Femina - May 24th, 2022
- Anti-Aging Products and Therapies Market Size Estimated to Reach $93.2 Billion by 2027 - Digital Journal - April 2nd, 2022
- Learning from the single cell: A new technique to unravel gene regulation - EurekAlert - April 2nd, 2022
- Sailing the Genome in Search of Safe Harbors - Technology Networks - April 2nd, 2022
- 7 Easy Ways to Transition Your Skin Care Routine for Spring - Vancouver Magazine - April 2nd, 2022
- INTERNATIONAL STEM CELL CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - April 2nd, 2022
- Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT - December 9th, 2021
- Benefits of Pulsed Laser-based Skin Therapy - Newswise - December 9th, 2021
- Mesoblast has long been the one poster child for stem cell therapy. Now Cynata and other ASX stocks have e ... - Stockhead - December 9th, 2021
- In This Issue - pnas.org - December 9th, 2021
- UNM research team finds lungfish cocoon is living tissue with antimicrobial functions - UNM Newsroom - December 9th, 2021
- Mini-brain model of frontotemporal dementia demonstrates the stages of dysfunction that lead to cell death - National Institute on Aging - November 7th, 2021
- A major research project to advance regenerative therapy for epidermolysis bullosa (EB) using transgenic stem cells - PR Web - November 7th, 2021
- 15 Best Peptide Skin-Care Products 2021 for Smoother, Firmer, and Plumper Skin - Allure - November 7th, 2021
- Lab-Growing Everything Might Be The Only Way To Attain A Sustainable World - Intelligent Living - November 7th, 2021
- Common But Overlooked Causes for Hair Loss - The Cherokee Scout - November 7th, 2021
- How To Look Less Tired According To Experts | Grazia - Grazia - November 7th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Stem cells may be the key to saving white rhinos from extinction - Sciworthy - October 5th, 2021
- The Best Skincare Treatments For Time-Crunched Moms (Or Anyone Else Who Only Has Five Minutes To Spare) - Forbes - October 5th, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 5th, 2021
- 3 of the Best Fall Beauty Buys - Pursuitist - October 5th, 2021
- Can Obesity Lead to Hair Fall? Here's What The Research Says - India.com - October 5th, 2021
- 12 of the best face serums 2021 - Medical News Today - October 5th, 2021
- The Number 1 Serum in the U.S. Is on Sale at SaksAlong With Other Never-Discounted Buys - Well+Good - October 5th, 2021
- Man discovers nasty red rash on his hands and elbows is potentially fatal - The Mirror - October 5th, 2021